Antimicrobial resistance (AMR) is regarded as one of the greatest issues facing 21st century global healthcare. Due to the misuse and overuse of antibiotics AMR has rapidly disseminated worldwide resulting in untreatable infections in healthcare settings.
In order to limit the emergence of antibiotic resistance bacteria, effective and cost effective solutions are required to guide the appropriate use of antibiotics. Mast Group Ltd. supports tackling the AMR challenge and accordingly for many years has continually updated its portfolio of products.
Products incorporate a variety of applications to enable screening for the presence or absence of resistant bacteria and confirmatory tests for implementation of infection control measures to limit the spread of resistant pathogens.
- Colorimetric test MAST® CARBA PacE for rapid carbapenemase detection in less than 10 minutes in Pseudomonas spp., Acinetobacter spp. and Enterobacterales
- Combination disc technology MASTDISCS® Combi for confirmation and differentiation of ß-lactamase mediated resistant enzymes including AmpC, ESBL, MBL, KPC and OXA-48 like carbapenemases in Enterobacterales
- MASTDISCS® ID and MASTDISCS® AST Products used as a screening tool for an indication of the presence of resistant enzymes including AmpC, ESBL, MBL, KPC and OXA-48-like carbapenemases in Enterobacterales, Acinetobacter and Pseudomonas spp. Also disc diffusion products for the detection of emergence of penicillin resistance and high level aminoglycoside resistance.